Considering the role of heparin and low-molecular-weight heparins in acute ischemic stroke

Stroke

Volumn 33, Issue 7, 2002, Pages 1927-1933

  Fisher, Marc ^a   Moonis, Majaz ^a  

^a Memorial Health   (United States)

Author keywords

Anticoagulants; Heparin; Stroke, acute; Stroke, ischemic; Warfarin

Indexed keywords

CERTOPARIN; DALTEPARIN; DANAPAROID; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; TINZAPARIN;

ACUTE HEART INFARCTION; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; EARLY DIAGNOSIS; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK BENEFIT ANALYSIS; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0036317723     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000019422.63054.5F     Document Type: Article

References (51)

1. Is there still a role for intravenous heparin in acute stroke? No
2. Acute ischemic stroke and heparin treatments
3. When should heparin be given to patients with atrial fibrillation-related embolic brain infarcts?
4. Intravenous heparin in acute stroke
5. Aspirin, anticoagulants, and hemorrhagic conversion of ischemic infarction: Hypothesis and implications
6. Anticoagulant, fibrinolytic and antiplatelet therapy
7. Choice of endpoints in antiplatelet trials: Which outcomes are most relevant to stroke patients?
8. Hemorrhagic transformation: The spectrum of ischemia-related brain hemorrhage
9. Cardiogenic brain embolism: The second report of the Cerebral Embolism Task Force
10. Safety of heparin in acute ischemic stroke
11. Hemorrhagic infarcts
12. Recurrent embolic cerebral infarction and anticoagulation
13. Determinants of early recurrence of cerebral infarction: The Stroke Data Bank
14. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke
15. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: A randomized controlled trial: The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators
16. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: Results of the TOPAS trial
17. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: The Northern Manhattan Stroke Study
18. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: A double-blind randomised study: HAEST Study Group Heparin in Acute Embolic Stroke Trial
19. Intravenous heparin for acute stroke: What can we learn from the megatrials?
20. Cardiogenic brain embolism: Cerebral Embolism Task Force
21. Peripheral emboli from left ventricular thrombi of different echocardiographic appearance in acute myocardial infarction
22. Left ventricular thrombosis and cerebrovascular accident in acute myocardial infarction
23. Increased occurrence of left ventricular thrombi during early treatment with timolol in patients with acute myocardial infarction
24. Left ventricular thrombi after short-term high-dose anticoagulants in acute myocardial infarction
25. Prophylactic anticoagulation for LV thrombi after AM1
26. Risk factors for embolisation in patients with left ventricular thrombi and acute myocardial infarction
27. Relationship between apparent diffusion coefficient and subsequent hemorrhagic transformation following acute ischemic stroke
28. Hemorrhagic transformation in cardioembolic cerebral infarction
29. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke
30. Immediate anticoagulation with heparin for first-ever ischemic stroke in the carotid artery territories observed within 5 hours of onset
31. Failure of heparin to prevent progression in progressing ischemic infarction
32. Interpretation of IST and CAST stroke trials. International Stroke Trial: Chinese Acute Stroke Trial
33. Heparin in acute stroke with atrial fibrillation: Clinical relevance of very early treatment
34. Heparin in acute ischemic stroke: The case for a new clinical trial
35. Low-molecular-weight heparin for the treatment of acute ischemic stroke
36. Fraxiparine in ischemic stroke study (FISSbis): 7th European Stroke Conference; May 27-30
37. Tinzaparin in acute ischemic stroke (TAIST): A randomized aspirin controlled trial
38. Anticoagulants for acute ischaemic stroke
39. Comparison of the acute-phase response in patients with ischemic stroke treated with high-dose heparin or aspirin
40. Safety of anticoagulation after hemorrhagic infarction
41. The clinical spectrum of hemorrhagic infarction
42. Thromboembolism and antithrombotic therapy in cerebrovascular disease
43. Catalepsy after stroke
44. Anticoagulant-induced intracerebral bleeding in brain ischemia: Evaluation in 200 patients with TIAs, emboli from the heart, and progressing stroke
45. Early spontaneous hematoma in cerebral infarct: Is primary cerebral hemorrhage overdiagnosed?
46. Hemorrhagic transformation in cerebral embolism
47. Cardiogenic brain embolism: The second report of the Cerebral Embolism Task Force
48. Anticoagulant-related hemorrhage in acute cerebral embolism
49. Immediate anticoagulation of embolic stroke: Brain hemorrhage and management options: Cerebral Embolism Study Group
50. Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: Results of GUSTO-1: Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries